Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Apr:177:156489.
doi: 10.1016/j.metabol.2025.156489. Epub 2026 Jan 8.

Global glucagon-like peptide-2 receptor activation linked to increased obesity risk in the UK Biobank

Peter A Gerlach  1 , Sarina Gadgaard  2 , Jakob S Madsen  3 , Peter Lindquist  2 , Javier Sanchez Lorente  3 , Felix Faas  2 , Maria B N Gabe  2 , Mette M Rosenkilde  4 , Alexander S Hauser  5
Affiliations
Free article

Global glucagon-like peptide-2 receptor activation linked to increased obesity risk in the UK Biobank

Peter A Gerlach et al. Metabolism. 2026 Apr.
Free article

Abstract

Objective: The glucagon-like peptide-2 receptor (GLP-2R) is recognized as a potential target for the treatment of obesity and type 2 diabetes (T2D). Yet, the impact and mechanism of GLP-2R activation on these metabolic traits remain unclear in humans.

Methods: We conducted in vitro pharmacological characterization of 30 naturally occurring GLP-2R missense variants identified from the UK Biobank, assessing receptor activity via cyclic adenosine monophosphate (cAMP) production and β-arrestin 2 recruitment. To study the effect of GLP-2R activation on metabolic traits, we categorized variants into functional groups based on their signaling profiles and performed genetic association tests in ∼500,000 UK Biobank participants.

Results: We experimentally identified variants with both increased and decreased effects on receptor signaling and computationally identified an additional 34 predicted Loss-of-Function (pLoF) variants. Notably, the most frequent GLP-2R variant, D470N, with an allele frequency of 32% in the UK population, displayed increased cAMP production. Mechanistically, the increased cAMP production of D470N is likely linked to reduced β-arrestin recruitment and reduced internalization. Genetic associations showed that D470N was linked to increased risk of obesity, T2D, and higher Body Mass Index (BMI), body fat, glycated hemoglobin (HbA1c), and diastolic/systolic blood pressure. In contrast, Loss-of-Function (LoF) variants were associated with a decreased risk of obesity and reduced body fat percentage.

Conclusion: Our findings suggest that global GLP-2R activation, encompassing the effects across all tissues, is associated with increased risk of obesity. This study highlights the role of the GLP-2R in metabolic diseases, guiding the future development of biased GLP-2R ligands and the potential adverse effects of GLP-2R modulation.

Keywords: GLP-2R; Obesity; SNP; T2D;GPCR; UK Biobank.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Mette Marie Rosenkilde reports financial support was provided by European Foundation for the Study of Diabetes. Mette Marie Rosenkilde reports financial support was provided by Novo Nordisk Foundation. Alexander Sebastian Hauser reports financial support was provided by Lundbeck Foundation. MMR is a minority shareholder and a cofounder of Antag Therapeutics and Bainan Biotech, and chair of the Board of Directors of Bainan Biotech, has served on scientific advisory panels for and/or has received speaker honoraria from AlphaSights. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Substances

LinkOut - more resources